MAR - 9 1999

NDA 17-854/S-039
NDA 17-862/S-042
NDA 18-821/S-018

Wyeth-Ayerst Laboratories
Attention: Nanette E. Holston
P.O. Box 8299
Philadelphia, PA 19 10 l-8299

Dear Ms. Holston:

Please refer to your supplemental new drug applications dated September 8, 1998, received September 10, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Reglan (metoclopramide) Tablets, Injection, and Syrup, respectively.

We note that these supplements were submitted as 'Special Supplement - Changes Being Effected' under 21 CFR 314.70(c).

These supplemental new drug applications provide for revision of both the oral products package insert, as well as the injection product insert to include "possible AV block" in the ADVERSE REACTIONS section, Cardiovascular subsection. The supplements were submitted in response to our July 5, 1998 letter, and your submissions stated the week of October 5, 1998 as the implementation date for the change.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted final printed labeling (package inserts submitted September 8, 1998). Accordingly, these supplemental applications are approved effective on the date of this letter.

We note that the ADMIXTURE COMPATIBILITIES section of the package inserts lists multiple electrolytes and drugs, by specific manufacturer, with which Reglan Injection is compatible. In a February 19, 1999 telephone conversation with Ms. Melodi McNeil, of this Division, Mr. John Seneca, of your firm, indicated that several electrolytes and drugs (Potassium Chloride, USP; Magnesium Sulfate, USP; Aminophylline, USP; Methylprednisoline Sodium Succinate, USP, and Calcium Gluconate, USP) have been deleted from the ADMIXTURE COMPATIBILITIES section of the inserts because they are no longer manufactured by ESI.

Please evaluate the compatibility of Reglan Injection with the drugs and electrolvtes listed above, as well as the others listed in the ADMIXTURE COMPATIBILITES section, in general. rather than by specific manufacturer. Please provide this evaluation to us and consider whether revision of the insert to remove the names of specific manufacturers is warranted.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF.2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Melodi McNeil, Regulatory Health Project Manager, at (301) 827-73 10.

Sincerely,

LT 3-9-99 MM 3/9/99

Lilia Talarico, M.D.
Director
Division of Gastrointestinal and Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research